APA (7th ed.) Citation

Westin, S. N., Labrie, M., Litton, J. K., Blucher, A., Fang, Y., Vellano, C. P., . . . Mills, G. B. (2021). Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical cancer research, 27(23), 6354. https://doi.org/10.1158/1078-0432.CCR-21-1656

Chicago Style (17th ed.) Citation

Westin, Shannon N., et al. "Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer." Clinical Cancer Research 27, no. 23 (2021): 6354. https://doi.org/10.1158/1078-0432.CCR-21-1656.

MLA (9th ed.) Citation

Westin, Shannon N., et al. "Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer." Clinical Cancer Research, vol. 27, no. 23, 2021, p. 6354, https://doi.org/10.1158/1078-0432.CCR-21-1656.